Marktanalyse - Rheumatoid Arthritis - Pipeline Review, H2 2016

Global Markets Direct
12.2016
1186 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Rheumatoid Arthritis - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rheumatoid Arthritis — Pipeline Review, H2 2016, provides an overview of the Rheumatoid Arthritis (Immunology) pipeline landscape.

Rheumatoid arthritis (RA) is an autoimmune chronic disorder that eventually leads to destruction of bones causing deformities. Signs and symptoms of rheumatoid arthritis include tender, warm, swollen joints, fatigue, and fever and weight loss. Rheumatoid arthritis may be a result of genetic and certain specific environmental factors. Women are much more susceptible to develop RA. Treatment includes non-steroidal anti-inflammatory drugs, corticosteroid medications and immunosuppressants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rheumatoid Arthritis — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rheumatoid Arthritis (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rheumatoid Arthritis (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Rheumatoid Arthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 15, 28, 44, 59, 12, 223, 50 and 9 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 37 and 12 molecules, respectively.

Rheumatoid Arthritis (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rheumatoid Arthritis (Immunology).
- The pipeline guide reviews pipeline therapeutics for Rheumatoid Arthritis (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rheumatoid Arthritis (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rheumatoid Arthritis (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rheumatoid Arthritis (Immunology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rheumatoid Arthritis (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rheumatoid Arthritis (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 12

Rheumatoid Arthritis Overview 13

Therapeutics Development 14

Rheumatoid Arthritis - Therapeutics under Development by Companies 16

Rheumatoid Arthritis - Therapeutics under Investigation by Universities/Institutes 36

Rheumatoid Arthritis - Pipeline Products Glance 39

Rheumatoid Arthritis - Products under Development by Companies 43

Rheumatoid Arthritis - Products under Investigation by Universities/Institutes 72

Rheumatoid Arthritis - Companies Involved in Therapeutics Development 75

Rheumatoid Arthritis - Therapeutics Assessment 308

Drug Profiles 355

Rheumatoid Arthritis - Dormant Projects 1046

Rheumatoid Arthritis - Discontinued Products 1098

Rheumatoid Arthritis - Product Development Milestones 1110

Appendix 1134





List of Tables

Number of Products under Development for Rheumatoid Arthritis, H2 2016 65

Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016 66

Number of Products under Development by Companies, H2 2016 68

Number of Products under Development by Companies, H2 2016 (Contd..1) 69

Number of Products under Development by Companies, H2 2016 (Contd..2) 70

Number of Products under Development by Companies, H2 2016 (Contd..3) 71

Number of Products under Development by Companies, H2 2016 (Contd..4) 72

Number of Products under Development by Companies, H2 2016 (Contd..5) 73

Number of Products under Development by Companies, H2 2016 (Contd..6) 74

Number of Products under Development by Companies, H2 2016 (Contd..7) 75

Number of Products under Development by Companies, H2 2016 (Contd..8) 76

Number of Products under Development by Companies, H2 2016 (Contd..9) 77

Number of Products under Development by Companies, H2 2016 (Contd..10) 78

Number of Products under Development by Companies, H2 2016 (Contd..11) 79

Number of Products under Development by Companies, H2 2016 (Contd..12) 80

Number of Products under Development by Companies, H2 2016 (Contd..13) 81

Number of Products under Development by Companies, H2 2016 (Contd..14) 82

Number of Products under Development by Companies, H2 2016 (Contd..15) 83

Number of Products under Development by Companies, H2 2016 (Contd..16) 84

Number of Products under Development by Companies, H2 2016 (Contd..17) 85

Number of Products under Development by Companies, H2 2016 (Contd..18) 86

Number of Products under Investigation by Universities/Institutes, H2 2016 87

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 88

Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 89

Comparative Analysis by Late Stage Development, H2 2016 90

Comparative Analysis by Clinical Stage Development, H2 2016 91

Comparative Analysis by Early Stage Development, H2 2016 92

Comparative Analysis by Unknown Stage Development, H2 2016 93

Products under Development by Companies, H2 2016 94

Products under Development by Companies, H2 2016 (Contd..1) 95

Products under Development by Companies, H2 2016 (Contd..2) 96

Products under Development by Companies, H2 2016 (Contd..3) 97

Products under Development by Companies, H2 2016 (Contd..4) 98

Products under Development by Companies, H2 2016 (Contd..5) 99

Products under Development by Companies, H2 2016 (Contd..6) 100

Products under Development by Companies, H2 2016 (Contd..7) 101

Products under Development by Companies, H2 2016 (Contd..8) 102

Products under Development by Companies, H2 2016 (Contd..9) 103

Products under Development by Companies, H2 2016 (Contd..10) 104

Products under Development by Companies, H2 2016 (Contd..11) 105

Products under Development by Companies, H2 2016 (Contd..12) 106

Products under Development by Companies, H2 2016 (Contd..13) 107

Products under Development by Companies, H2 2016 (Contd..14) 108

Products under Development by Companies, H2 2016 (Contd..15) 109

Products under Development by Companies, H2 2016 (Contd..16) 110

Products under Development by Companies, H2 2016 (Contd..17) 111

Products under Development by Companies, H2 2016 (Contd..18) 112

Products under Development by Companies, H2 2016 (Contd..19) 113

Products under Development by Companies, H2 2016 (Contd..20) 114

Products under Development by Companies, H2 2016 (Contd..21) 115

Products under Development by Companies, H2 2016 (Contd..22) 116

Products under Development by Companies, H2 2016 (Contd..23) 117

Products under Development by Companies, H2 2016 (Contd..24) 118

Products under Development by Companies, H2 2016 (Contd..25) 119

Products under Development by Companies, H2 2016 (Contd..26) 120

Products under Development by Companies, H2 2016 (Contd..27) 121

Products under Development by Companies, H2 2016 (Contd..28) 122

Products under Investigation by Universities/Institutes, H2 2016 123

Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 124

Products under Investigation by Universities/Institutes, H2 2016 (Contd..2) 125

Rheumatoid Arthritis - Pipeline by 3SBio Inc, H2 2016 126

Rheumatoid Arthritis - Pipeline by 4D Pharma Plc, H2 2016 127

Rheumatoid Arthritis - Pipeline by A&G Pharmaceutical Inc, H2 2016 128

Rheumatoid Arthritis - Pipeline by AB Science SA, H2 2016 129

Rheumatoid Arthritis - Pipeline by AB2 Bio Ltd, H2 2016 130

Rheumatoid Arthritis - Pipeline by AbbVie Inc, H2 2016 131

Rheumatoid Arthritis - Pipeline by Ablynx NV, H2 2016 132

Rheumatoid Arthritis - Pipeline by ACEA Biosciences Inc, H2 2016 133

Rheumatoid Arthritis - Pipeline by Addex Therapeutics Ltd, H2 2016 134

Rheumatoid Arthritis - Pipeline by Adello Biologics LLC, H2 2016 135

Rheumatoid Arthritis - Pipeline by Advinus Therapeutics Ltd, H2 2016 136

Rheumatoid Arthritis - Pipeline by AlphaMab Co Ltd, H2 2016 137

Rheumatoid Arthritis - Pipeline by Alteogen Inc, H2 2016 138

Rheumatoid Arthritis - Pipeline by Amgen Inc, H2 2016 139

Rheumatoid Arthritis - Pipeline by Amura Holdings Ltd, H2 2016 140

Rheumatoid Arthritis - Pipeline by Anacor Pharmaceuticals Inc, H2 2016 141

Rheumatoid Arthritis - Pipeline by AnGes MG Inc, H2 2016 142

Rheumatoid Arthritis - Pipeline by Applied Genetic Technologies Corp, H2 2016 143

Rheumatoid Arthritis - Pipeline by Aptevo Therapeutics Inc, H2 2016 144

Rheumatoid Arthritis - Pipeline by ARA Healthcare Pvt Ltd, H2 2016 145

Rheumatoid Arthritis - Pipeline by Arena Pharmaceuticals Inc, H2 2016 146

Rheumatoid Arthritis - Pipeline by arGEN-X BV, H2 2016 147

Rheumatoid Arthritis - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 148

Rheumatoid Arthritis - Pipeline by Arthrogen BV, H2 2016 149

Rheumatoid Arthritis - Pipeline by Asahi Kasei Pharma Corp, H2 2016 150

Rheumatoid Arthritis - Pipeline by Asana BioSciences LLC, H2 2016 151

Rheumatoid Arthritis - Pipeline by Astellas Pharma Inc, H2 2016 152

Rheumatoid Arthritis - Pipeline by AstraZeneca Plc, H2 2016 153

Rheumatoid Arthritis - Pipeline by Atlantic Bio Sci LLC, H2 2016 154

Rheumatoid Arthritis - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016 155

Rheumatoid Arthritis - Pipeline by Avexxin AS, H2 2016 156

Rheumatoid Arthritis - Pipeline by Axxam SpA, H2 2016 157

Rheumatoid Arthritis - Pipeline by BCN Peptides SA, H2 2016 158

Rheumatoid Arthritis - Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2016 159

Rheumatoid Arthritis - Pipeline by Bio-Cancer Treatment International Ltd, H2 2016 160

Rheumatoid Arthritis - Pipeline by Biocad, H2 2016 161

Rheumatoid Arthritis - Pipeline by Biocon Ltd, H2 2016 162

Rheumatoid Arthritis - Pipeline by Biokine Therapeutics Ltd, H2 2016 163

Rheumatoid Arthritis - Pipeline by BioLingus AG, H2 2016 164

Rheumatoid Arthritis - Pipeline by BioLite Inc, H2 2016 165

Rheumatoid Arthritis - Pipeline by Bionovis SA, H2 2016 166

Rheumatoid Arthritis - Pipeline by BioTherapeutics Inc, H2 2016 167

Rheumatoid Arthritis - Pipeline by Biozeus, H2 2016 168

Rheumatoid Arthritis - Pipeline by Bird Rock Bio Inc, H2 2016 169

Rheumatoid Arthritis - Pipeline by Boehringer Ingelheim GmbH, H2 2016 170

Rheumatoid Arthritis - Pipeline by Bristol-Myers Squibb Company, H2 2016 171

Rheumatoid Arthritis - Pipeline by Can-Fite BioPharma Ltd, H2 2016 172

Rheumatoid Arthritis - Pipeline by Cardax Inc, H2 2016 173

Rheumatoid Arthritis - Pipeline by CASI Pharmaceuticals Inc, H2 2016 174

Rheumatoid Arthritis - Pipeline by CEL-SCI Corp, H2 2016 175

Rheumatoid Arthritis - Pipeline by Celgene Corp, H2 2016 176

Rheumatoid Arthritis - Pipeline by Cellceutix Corp, H2 2016 177

Rheumatoid Arthritis - Pipeline by Celldex Therapeutics Inc, H2 2016 178

Rheumatoid Arthritis - Pipeline by Celltrion Inc, H2 2016 179

Rheumatoid Arthritis - Pipeline by ChemoCentryx Inc, H2 2016 180

Rheumatoid Arthritis - Pipeline by Chipscreen Biosciences Ltd, H2 2016 181

Rheumatoid Arthritis - Pipeline by ChironWells GmbH, H2 2016 182

Rheumatoid Arthritis - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2016 183

Rheumatoid Arthritis - Pipeline by CJ HealthCare Corp, H2 2016 184

Rheumatoid Arthritis - Pipeline by Clevexel Pharma SA, H2 2016 185

Rheumatoid Arthritis - Pipeline by CLL Pharma SA, H2 2016 186

Rheumatoid Arthritis - Pipeline by Coherus BioSciences Inc, H2 2016 187

Rheumatoid Arthritis - Pipeline by Commence Bio Inc, H2 2016 188

Rheumatoid Arthritis - Pipeline by Compugen Ltd, H2 2016 189

Rheumatoid Arthritis - Pipeline by Confluence Life Sciences Inc, H2 2016 190

Rheumatoid Arthritis - Pipeline by CSL Ltd, H2 2016 191

Rheumatoid Arthritis - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2016 192

Rheumatoid Arthritis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016 193

Rheumatoid Arthritis - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 194

Rheumatoid Arthritis - Pipeline by Diamyd Medical AB, H2 2016 195

Rheumatoid Arthritis - Pipeline by Domainex Ltd, H2 2016 196

Rheumatoid Arthritis - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2016 197

Rheumatoid Arthritis - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016 198

Rheumatoid Arthritis - Pipeline by Eisai Co Ltd, H2 2016 199

Rheumatoid Arthritis - Pipeline by Eli Lilly and Company, H2 2016 200

Rheumatoid Arthritis - Pipeline by Enceladus Pharmaceuticals BV, H2 2016 201

Rheumatoid Arthritis - Pipeline by Endocyte Inc, H2 2016 202

Rheumatoid Arthritis - Pipeline by Enzene Biosciences Ltd, H2 2016 203

Rheumatoid Arthritis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 204

Rheumatoid Arthritis - Pipeline by Fountain Biopharma Inc, H2 2016 205

Rheumatoid Arthritis - Pipeline by Galapagos NV, H2 2016 206

Rheumatoid Arthritis - Pipeline by Gene Techno Science Co Ltd, H2 2016 207

Rheumatoid Arthritis - Pipeline by Genentech Inc, H2 2016 208

Rheumatoid Arthritis - Pipeline by Genor BioPharma Co Ltd, H2 2016 209

Rheumatoid Arthritis - Pipeline by Genosco Inc, H2 2016 210

Rheumatoid Arthritis - Pipeline by Gilead Sciences Inc, H2 2016 211

Rheumatoid Arthritis - Pipeline by GlaxoSmithKline Plc, H2 2016 212

Rheumatoid Arthritis - Pipeline by Griffin Discoveries BV, H2 2016 213

Rheumatoid Arthritis - Pipeline by Han Wha Pharma Co Ltd, H2 2016 214

Rheumatoid Arthritis - Pipeline by Handok Inc, H2 2016 215

Rheumatoid Arthritis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016 216

Rheumatoid Arthritis - Pipeline by Hansa Medical AB, H2 2016 217

Rheumatoid Arthritis - Pipeline by Hanwha Chemical Corp, H2 2016 218

Rheumatoid Arthritis - Pipeline by HEC Pharm Co Ltd, H2 2016 219

Rheumatoid Arthritis - Pipeline by Hetero Drugs Ltd, H2 2016 220





List of Figures

Number of Products under Development for Rheumatoid Arthritis, H2 2016 65

Number of Products under Development for Rheumatoid Arthritis - Comparative Analysis, H2 2016 66

Number of Products under Development by Companies, H2 2016 67

Number of Products under Investigation by Universities/Institutes, H2 2016 87

Comparative Analysis by Late Stage Development, H2 2016 90

Comparative Analysis by Clinical Stage Development, H2 2016 91

Comparative Analysis by Early Stage Products, H2 2016 92

Assessment by Monotherapy Products, H2 2016 359

Number of Products by Top 10 Targets, H2 2016 361

Number of Products by Stage and Top 10 Targets, H2 2016 361

Number of Products by Top 10 Mechanism of Actions, H2 2016 381

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 381

Number of Products by Top 10 Routes of Administration, H2 2016 402

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 402

Number of Products by Top 10 Molecule Types, H2 2016 404

Number of Products by Stage and Top 10 Molecule Types, H2 2016 404

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus